However, the expression cytotoxic T-lymphocyte-associated protein 4 (CTLA4), which is also an important immune checkpoint that could be a potential therapeutic target, is downregulated in the tumor group and upregulated in cluster 2 (Figures 2D,E). Here, CTLA4 is linked to neoplasm.